Results 121 to 130 of about 18,762 (211)

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata The BRAVE-AA1 Randomized Clinical Trial [PDF]

IMPORTANCE Baricitinib has demonstrated efficacy for treating severe alopecia areata in adults. There is currently limited information about the need for continuous therapy after achieving scalp hair regrowth.
Ball S., Dutronc Y., King B., Ko J., Kwon O., Liu C., Mesinkovska N. A., Piraccini B. M., Somani N., Vano-Galvan S., Yu G.   +10 more
core   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Viral Mechanisms and Drug Influences on Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Human Coronaviruses Infection: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aim Janus kinases/signal transducers and activators of transcription (JAK/STAT) pathway is crucial for various stages of immunity, from innate to adaptive responses. Type 1 IFNs activate JAK/STAT pathway by binding to receptors on JAK, phosphorylating STAT and upregulating interferon‐stimulated genes (ISGs) leading to cytokines ...
Esimebia Adjovi Amegashie, Ruth Oyawole Sikeola, Caleb Koranteng Kwayisi‐Darkwah, Gabriel Atampugbire, Emmanuel Ayitey Tagoe, Elijah Paintsil, Kwasi Torpey, Osbourne Quaye   +7 more
wiley   +1 more source

Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects

RMD Open
Objective Obesity and age are strongly linked to severe COVID-19 pneumonia where immunomodulatory agents including Janus kinase inhibitors have shown benefits but the efficacy of such therapy in viral pneumonia is not well understood.
Abdulla Watad, Dennis G McGonagle, Howard Amital, Tom Macleod, Or Hen, Paula David, Niv Ben-Shabbat   +6 more
doaj   +1 more source

Innate Lymphoid Cells in Tissue Homeostasis and Diseases

MedComm, Volume 7, Issue 5, May 2026.
Innate lymphoid cells (ILCs) are a heterogeneous group of immune cells with phenotypic and functional plasticity. ILCs dynamically regulate various immune cell types and play a crucial role in the pathophysiological processes of specific organs during sepsis. Targeting ILCs is a promising strategy for treating sepsis.
Zhenzhen Zhan, Heyang Sun, Chenning Li, Qianya Hong, Shuainan Zhu, Ying Yu, Hao Zhang, Kefang Guo   +7 more
wiley   +1 more source

Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care

Diseases
COVID-19 infection is caused by the novel severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2). This novel virus has transformed into different resistant variants (e.g., omicron; delta; alpha; epsilon) since its first emergence in 2019.
Cucnhat P. Walker, Natalie P. Hurlock, Subrata Deb   +2 more
doaj   +1 more source

Real‐World Outcomes of Baricitinib and Ritlecitinib in Refractory Alopecia Areata: Response Predictors and Relapse After Discontinuation or Dose Reduction

The Journal of Dermatology, Volume 53, Issue 5, Page 746-757, May 2026.
ABSTRACT Baricitinib and ritlecitinib are newly approved systemic Janus kinase (JAK) inhibitors for severe, refractory alopecia areata (AA). Although clinical trials have demonstrated their efficacy, real‐world evidence remains limited, particularly regarding predictors of response and outcomes following treatment interruption or dose tapering.
Rina Hayashi, Saori Takamura, Tomoo Fukuda   +2 more
wiley   +1 more source

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

Aging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu, Ming Yang, Fugang Xiao, Jinrong Zeng   +3 more
wiley   +1 more source

Real‐World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi‐Center Cohort Study

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT The approval of baricitinib and ritlecitinib for alopecia areata (AA) marks the beginning of the Janus kinase (JAK) inhibitor era in AA treatment. Tofacitinib, a first‐generation JAK1/3 inhibitor, has theoretical potential to treat AA; however, real‐world evidence, particularly on comparative outcomes across patient subgroups and patient ...
Yifan Jin, Juanmei Cao, Sai Yang, Yinghui Liu, Rong Tang, Yufang Zeng, Changzheng Huang, Ying Luo   +7 more
wiley   +1 more source

Baricitinib Mitigates Methotrexate-Induced Liver Fibrosis Model via YAP Pathway

Medicina
Background and Objectives: Liver fibrosis, a chronic process caused by various pathogenic factors, including drug toxicity, metabolic disorders, and chronic inflammation, is associated with liver-related mortality rates worldwide. It has been established
Mehmet Ulusan, Mumin Alper Erdogan, Ozkan Simsek, Zafer Dogan, Bertug Bekir Ciftci, Gultekin Atalan, Oytun Erbas   +6 more
doaj   +1 more source